Chinese pharma groups partner in $150M licensing deal; Pfizer to join lawsuit on tariffs
Chinese pharma group Alphamab Oncology announced yesterday that its subsidiary signed a contract worth potentially as much as $150 million with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
